.Johnson & Johnson's deprioritization of its own infectious disease pipeline has actually stated an additional victim in the form of its dengue virus vaccine mosnodenvir.Mosnodenvir is made to block out interactions between two dengue virus proteins. The injection made it through J&J's selection in 2015 to combine its contagious condition and vaccination operations, which viewed the likes of a late-stage respiratory system syncytial virus program went down coming from the Huge Pharma's pipe and also an E. coli injection sold to Sanofi.Mosnodenvir has actually possessed a rough time in the center, with J&J ending one litigation due to the impact of COVID-19 on application and stopping briefly employment in another research study in 2022. Yet the loyalty to mosnodenvir appeared to pay in Oct 2023, when the injection was shown to cause a dose-dependent antiviral effect on the detectability as well as beginning of dengue infection serotype 3 in a period 2 trial.
That data drop does not seem to have actually sufficed to spare mosnodenvir for long, along with the Big Pharma announcing today that it is discontinuing a follow-up stage 2 field research. The decision is associated with a "key reprioritization of the firm's pandemic ailments R&D profile," added J&J, which emphasized that no protection issues had actually been actually recognized." Johnson & Johnson will certainly remain to support the aggression versus dengue through sharing research results along with the health care neighborhood down the road," the pharma pointed out in the release.J&J had actually been actually acquiring dengue for over a years, featuring launching a Gps Center for Global Wellness Breakthrough at the Duke-NUS Medical School in Singapore in 2022. The center has been actually concentrated on accelerating early-stage exploration study to "deal with the growing difficulty of flaviviruses" including dengue and also Zika.